Get the app!
Back to Trades
Sell4

Pacira BioSciences, Inc.

PCRX

Total Value
$699.3K
Net $302.6K sold
Sales
$302.6K
3 transactions

Company Information

Ticker Symbol
PCRX
CIK
0001396814

Insider Information

Role
Chief Financial Officer
Officer
Location
BRISBANE, CA

Filing Details

Filing Date
Apr 22, 2026
Transaction Date
Apr 20, 2026
Accession Number
0001628280-26-026669
Form Type
4
Net Trading Amount
-$302.6K

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Apr 20, 2026Common Stock7,714$16.45Exercise$126.9K
Apr 20, 2026Common Stock7,714$25.14Sale$193.9K
Apr 21, 2026Common Stock2,845$16.45Exercise$46.8K
Apr 21, 2026Common Stock2,845$25.01Sale$71.2K
Apr 22, 2026Common Stock1,500$16.45Exercise$24.7K
Apr 22, 2026Common Stock1,500$25.01Sale$37.5K

Derivative Transactions

DateSecuritySharesExercise PriceTypeValue
Apr 20, 2026Derivative7,714$16.45Exercise$126.9K
Apr 21, 2026Derivative2,845$16.45Exercise$46.8K
Apr 22, 2026Derivative1,500$16.45Exercise$24.7K

Footnotes

  1. (F1)The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.
  2. (F2)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.31, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3.
  3. (F3)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.04, inclusive.
  4. (F4)The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.